Personalized Nanovaccine
Readiness
TRL 5 · SRL 5 · gap 0
Gap = technical readiness − societal readiness. Positive: the technology is ready and society is not. Negative: society wants it more than the technology can deliver.
Not scored. Watchlist entries do not enter any gradient.
Vaccines built at nanoscale and tailored to an individual — most seriously, cancer vaccines designed against the specific mutations in one patient's tumour.
The mechanism is now demonstrated rather than theoretical. A tumour is sequenced, the mutations that distinguish it from healthy tissue are identified, and a vaccine is manufactured to teach the immune system to recognise those specific targets. Trials in melanoma and pancreatic cancer have reported encouraging results, and the mRNA platforms built during the pandemic are the manufacturing base.
Readiness sits at 5 on each axis, and the constraint is logistical rather than scientific: each dose is a manufacturing run for one person, on a clock set by how fast the disease progresses. That is a supply chain no health system is built for, and Chapter 16's point about intangibles applies — the value sits in a process, not in a product that can be stocked.
Common misconception: that personalisation means expensive forever. The cost driver is turnaround time, and automation of the manufacturing step is the lever.
What it does
mechanism — not yet written. Published as missing rather than hidden.